The Division of Clinical Pharmacology's primary focus is the prevention and treatment of Atherosclerosis and Hypercholesterolemia. The division is led by Dr. Patrick Moriarty, who is one of the world's foremost authorities on LDL-apheresis, a procedure that filters the plasma resulting in an acute reduction of LDL cholesterol, markers of inflammation, and blood rheology.
Additional staff includes pharmacists, clinical nurses, a dietitian, ultrasound technician and research study coordinators.
Dr. Moriarty's research interests include atherosclerosis, vascular inflammation, and blood rheology. He has completed over 75 clinical research studies as principal investigator or co-investigator. Research grants involve hyperlipidemia, hypertension, diabetes, post-menopause, and obesity.
He also participates in research related to LDL-apheresis and its potential use for congestive heart failure, acute coronary syndrome, retinal artery occlusion, and peripheral vascular disease. He has published extensively, sits on the editorial board of the Journal of Clinical Apheresis and Future Lipidology, and has successfully established his own clinic at the University of Kansas Medical Center for the treatment and prevention of vascular disease.